

The challenge and the opportunity of cardio-oncology: When cardiovascular disease and cancer intersect.

Andishe Kearns*

Department of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK

Abstract

Cardiovascular disease and cancer are two leading causes of mortality and morbidity worldwide. Traditionally, these diseases have been viewed and managed separately, with little consideration for the potential interactions and overlap between them. However, recent advances in cancer treatments and improved survival rates have unveiled a complex interplay between cardiovascular health and cancer, giving rise to the emerging field of cardio-oncology. It will explore the challenge and opportunity of cardio-oncology, emphasizing the need for increased awareness, education, and research in this evolving field. By integrating cardiovascular and oncology care, healthcare providers can enhance patient outcomes, improve survivorship, and enhance quality of life for individuals affected by cancer and cardiovascular disease. A comprehensive understanding of the mechanisms underlying the cardiovascular-cancer connection will pave the way for novel therapeutic strategies and preventive interventions, ultimately improving patient care and outcomes in both fields.

Keywords: Cardio oncology, Cardio toxicity, Cancer, Integrative care.

Introduction

Cardiovascular disease and cancer are two prominent global health challenges, accounting for a significant burden of morbidity and mortality. Traditionally, these diseases have been approached and managed independently, with cardiovascular specialists focusing on heart-related conditions and oncologists primarily addressing cancer treatment. However, with advancements in cancer therapies and improved survival rates, it has become evident that there is a complex interplay between cardiovascular health and cancer. This intersection between cardiovascular disease and cancer has given rise to the emerging field of cardio-oncology [1].

The challenge of cardio-oncology lies in recognizing and managing the cardiovascular complications that arise during cancer treatment, as well as understanding the long-term effects of cancer therapies on cardiovascular health. Certain chemotherapy agents and targeted therapies have been linked to cardio toxicity, leading to adverse cardiovascular events such as heart failure, arrhythmias, and myocardial infarction. Additionally, radiation therapy can cause vascular damage and increase the risk of developing cardiovascular diseases. These complications not only impact the immediate well-being of cancer patients but also affect their long-term cardiovascular health and quality of life [2].

Moreover, cardio-oncology offers the potential to personalize cancer treatment strategies. Considering the individual patient's cardiovascular status and tailoring cancer therapies accordingly can help optimize treatment efficacy while

minimizing cardiovascular risks. This approach requires a comprehensive understanding of the underlying mechanisms that connect cardiovascular disease and cancer, enabling the development of novel therapeutic strategies and preventive interventions [3].

Healthcare professionals need to be aware of the potential cardiovascular complications associated with cancer treatment and be equipped with the knowledge and skills to manage them effectively. Additionally, ongoing research efforts are needed to explore the intricate mechanisms linking cardiovascular disease and cancer, paving the way for innovative approaches to patient care and improved outcomes in both fields [4,5].

Conclusion

The intersection of cardiovascular disease and cancer presents a unique challenge and a promising opportunity in the field of cardio-oncology. While the cardiovascular complications associated with cancer treatment pose significant challenges for patient care, the collaboration between cardiologists and oncologists offers an opportunity to improve outcomes and enhance the quality of life for individuals affected by both diseases.

Reference

1. Karlstaedt A, Barrett M, Hu R, et al. Cardio-oncology: Understanding the intersections between cardiac metabolism and cancer biology. *J Am Coll Cardiol Basic Trans.* 2021;6(8):705-18.

*Correspondence to Andishe Kearns, Department of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK, Email: andishe@kearns.uk

Received: 30-Jun-2023, Manuscript No. AAMOR-23-103539; Editor assigned: 03-July-2023, PreQC No. AAMOR-23-103539(PQ); Reviewed: 17-July-2023, QC No. AAMOR-23-103539; Revised: 21-July-2023, Manuscript No. AAMOR-23-103539(R); Published: 27-July-2023, DOI:10.35841/aamor-7.4.190

2. Okwuosa TM, Barac A. Burgeoning cardio-oncology programs: Challenges and opportunities for early career cardiologists/faculty directors. *J Am Coll Cardiol.* 2015;66(10):1193-7.
3. Campia U, Moslehi JJ, Amiri-Kordestani L, et al. Cardio-oncology: Vascular and metabolic perspectives: A scientific statement from the American Heart Association. *Circulation.* 2019;139(13):e579-602.
4. Rajkomar A, Dean J, Kohane I. Machine learning in medicine. *N Engl J Med.* 2019;380:1347-1358.
5. Rusch M, et al. Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. *Nat Commun.* 2018;9:3962.